En estos ensayos, Ozempic ha proporcionado una mayor reduccin de los niveles de glucosa en sangre (HbA1c) y del peso corporal en comparacin con otros tratamientos para la diabetes tipo 2 (sitagliptina, exenatida de liberacin prolongada, insulina glargina U100 y dulaglutida)[5-8], adems de demostrar beneficios cardiovasculares y una reduccin estadsticamente significativa de la aparicin o progresin de la nefropata diabtica frente a placebo conjuntamente con el tratamiento estndar[4]
Most irregularities are transient and benign
Mounjar o injection has cert ain drug interactions
Exenatide has a half-life of 3.34 h, and one dose is seen to be insufficient, so it is taken twice daily
Patients should contact their healthcare provider if they notice persistent lumps, significant pain, signs of infection (warmth, increasing redness, pus), or if they experience unexpected changes in their response to Zepbound